Lonza Group AG stock (CH0013841017): CDMO heavyweight back in focus after latest business update

Lonza Group AG has moved back into the spotlight after a recent trading update for 2025 and continued portfolio streamlining, keeping investors focused on margins, contract visibility and demand for biologics manufacturing.

Lonza Group AG has returned to investors’ radar after a business update on its 2025 outlook and order trends, which highlighted the continued importance of biologics and advanced therapies in its contract development and manufacturing portfolio, according to a trading statement published on 01/23/2025 by the company’s investor relations team and follow-up coverage from financial media on 01/24/2025Lonza investor relations as of 01/23/2025Reuters as of 01/24/2025.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza Group
• Sector/industry: Healthcare / contract development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Global pharmaceutical and biotechnology customers, including the US and Europe
• Key revenue drivers: Biologics manufacturing, small molecules, cell and gene technologies, capsules and health ingredients
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG’s business model is built around providing development and manufacturing services to pharmaceutical and biotechnology companies rather than marketing its own branded medicines. The company acts as a contract development and manufacturing organization, or CDMO, supporting customers from early-stage research through to commercial-scale production, according to its corporate description and latest annual report for the 2024 financial year published on 01/24/2025Lonza annual report as of 01/24/2025.

Under this model, Lonza earns revenue primarily through long-term contracts for development services, clinical supply and commercial manufacturing of active pharmaceutical ingredients, biologics and finished dosage forms. The company positions itself as a partner that can provide scalable capacity, regulatory expertise and technology platforms, which can help customers reduce time-to-market and manage complex production challengesLonza annual report as of 01/24/2025.

Lonza’s portfolio spans biologics, small molecules, cell and gene technologies, and capsules and health ingredients. Management has emphasized a strategy of focusing on businesses where the company sees sustainable demand and technological differentiation, and has continued to streamline the portfolio, including divestments of non-core activities, as highlighted by the completed sale of its stake in Micro-Macinazione SA reported in sector media during 2025Global Legal Chronicle as of 02/2025.

Main revenue and product drivers for Lonza Group AG

Lonza organizes its activities into segments that include biologics, small molecules, cell and gene technologies, and capsules and health ingredients. According to the 2024 annual report released on 01/24/2025, biologics manufacturing remained a key contributor to group revenue for the 2024 financial year, reflecting demand for monoclonal antibodies and other complex biologic drugs among large pharmaceutical and biotechnology clientsLonza annual report as of 01/24/2025.

In the biologics area, Lonza offers mammalian and microbial manufacturing, formulation and fill-and-finish services. This segment benefits from the trend toward targeted therapies and biologic drugs, many of which require specialized equipment and know-how. Contract manufacturers like Lonza can provide capacity that would be costly and time-consuming for drug developers to build internally, which has made the segment an important growth engine according to management comments during past results presentationsLonza annual report as of 01/24/2025.

Small molecules remain another core revenue stream. Lonza provides custom development and manufacturing of active pharmaceutical ingredients, including highly potent compounds. While the overall small-molecule market is more mature than biologics, steady demand for generic and branded medications continues to support utilization of Lonza’s manufacturing network, as described in the company’s business overview for 2024Lonza annual report as of 01/24/2025.

In the cell and gene technologies area, Lonza is active in manufacturing viral vectors, cell therapies and related advanced treatments. This business taps into emerging modalities such as CAR-T and gene therapies, where regulatory complexity and technical barriers create opportunities for specialized CDMOs. The company’s capsules and health ingredients unit supplies capsules and nutritional ingredients used by pharmaceutical and consumer health companies, adding a more diversified revenue base beyond pure drug substance manufacturingLonza annual report as of 01/24/2025.

Industry trends and competitive position

The broader CDMO industry has been shaped by increasing outsourcing of pharmaceutical development and manufacturing, as drugmakers seek flexibility and cost efficiency. Lonza is widely viewed as one of the larger global CDMO providers, competing with peers that include both diversified industrial groups and specialist contract manufacturers, according to sector research published over the 2024–2025 period by industry analystsSpherical Insights as of 2025.

Shift toward biologics, complex small molecules and advanced therapies is expected to support demand for high-quality CDMO services. At the same time, pricing pressure, regulatory scrutiny and the need to maintain high utilization of manufacturing assets can weigh on margins. Lonza’s strategy of focusing on segments with higher barriers to entry, alongside continued portfolio optimization, is designed to address these industry dynamics, according to management commentary in connection with the 2024 annual resultsLonza annual report as of 01/24/2025.

Competition in biologics manufacturing remains intense, with rival CDMOs and in-house capacities at major pharmaceutical companies. Lonza’s scale, geographic footprint and experience across different modalities are often cited as competitive strengths, but investors also follow capacity expansions in the sector closely, as overcapacity could pressure pricing in specific technology areas if demand growth slows.

Why Lonza Group AG matters for US investors

For US-based investors, Lonza Group AG offers exposure to the global pharmaceutical outsourcing trend through a company listed on the SIX Swiss Exchange. Many of Lonza’s key customers are large US and European pharmaceutical and biotech companies, which means the group is indirectly exposed to the dynamics of the US healthcare and life sciences markets, including R&D spending cycles and drug pipeline success ratesLonza annual report as of 01/24/2025.

Some US investors may access the stock via international brokerage accounts or through funds and ETFs that include Lonza in their portfolios. The company’s focus on biologics and advanced therapies aligns with areas that have been important growth engines for the US biotech sector in recent years. At the same time, foreign-exchange movements between the Swiss franc and US dollar can influence reported returns for investors based in the United States, adding an additional factor to consider.

Regulatory developments in the US, such as changes in drug pricing policies, approval frameworks or incentives for innovative therapies, can indirectly affect Lonza’s customers and thus demand for CDMO services. As a result, Lonza’s performance is not only tied to European market conditions but also to broader trends in the US healthcare ecosystem, which continues to be one of the most important revenue sources for global pharmaceutical and biotech companies.

Conclusion

Lonza Group AG remains one of the key players in the global CDMO industry, with a business model that is tightly linked to long-term partnerships across the pharmaceutical and biotechnology value chain. Its focus on biologics, small molecules and advanced therapies positions it in areas where demand has grown structurally, although competition and capacity cycles remain important watchpoints. For US investors, the stock offers indirect exposure to global drug development trends and outsourcing dynamics, while also incorporating currency and regulatory factors associated with a Swiss-listed healthcare manufacturing group.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.